Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Domestic sales of core products and new products, exports of Hemlibra to Roche and NEMLUVIO to Galderma, and royalty income related to NEMLUVIO increased. The ratio of cost of products sold to revenue improved due to changes in the product sales mix and foreign exchange effects. Research and development expenses increased as a result of investment in drug discovery and early-stage development and progress in development projects, while selling, general and administrative expenses increased due to temporary increases in various expenses and higher enterprise taxes.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥321,747 million (YoY +11.5%) |
| Operating profit | ¥158,765 million (YoY +16.2%) |
| Ordinary income | ¥160,197 million |
| Profit attributable to owners of the parent | ¥115,418 million (YoY +18.7%) |
| Net income per share | ¥70.13 |
| Equity ratio | End of the current fiscal period 84.2 / End of previous period 82.1 |
| Total assets | ¥2,265,101 million |
| Net assets | ¥1,907,715 million |
| Cash flows from operating activities | ¥122,040 million |
| Cash flows from investing activities | ¥113,796 million |
| Cash flows from financing activities | ¥-244,584 million |
| Cash and cash equivalents at end of period | ¥417,984 million |
| Full-year earnings forecast | Net Sales ¥1,345,000 million (YoY +6.9%) / Operating profit ¥670,000 million (Core) (YoY +7.5%) / Ordinary income Not disclosed / Net income ¥485,000 million (Core) (YoY +7.5%) |
| Annual Dividend Forecast | ¥272.00 (actual for the fiscal year ended December 2025) → ¥132.00 (forecast for the fiscal year ending December 2026) |
| Payout ratio | 44.7% (Core payout ratio) |
| Regional sales | Japan Sales of products and merchandise ¥111,429 million / Other revenue ¥166 million / Overseas expansion Sales of products and merchandise ¥180,148 million / Other revenue ¥30,005 million / Of which: Switzerland Sales of products and merchandise ¥171,783 million / Other revenue ¥27,639 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Held (for institutional investors, securities analysts and media organizations) |
| Issued Shares at Period-End | 1,679,057,667 |
| Treasury Shares at Period-End | 33,294,611 |
| Factors Behind Changes in Business Performance | Domestic sales of core products and new products, exports of Hemlibra to Roche and NEMLUVIO to Galderma, and royalty income related to NEMLUVIO increased. The ratio of cost of products sold to revenue improved due to changes in the product sales mix and foreign exchange effects. Research and development expenses increased as a result of investment in drug discovery and early-stage development and progress in development projects, while selling, general and administrative expenses increased due to temporary increases in various expenses and higher enterprise taxes. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Domestic sales of core products and new products, exports of Hemlibra to Roche and NEMLUVIO to Galderma, and royalty income related to NEMLUVIO increased. The ratio of cost of products sold to revenue also improved due to changes in the product sales mix and foreign exchange effects, while research and development expenses and selling, general and administrative expenses increased.